Use of liraglutide in the patient with obesity and type 2 diabetes mellitus: a literature review
Keywords:Liraglutide, Diabetes mellitus, GLP-1 receptor
Obesity and type 2 diabetes mellitus represent two of the most pressing public health challenges globally. In recent decades, an alarming increase in the prevalence of both conditions has been observed, which has led to a significant increase in the burden of disease and an increased search for effective therapeutic strategies. As evidence accumulates on the efficacy and safety of Liraglutide in this patient population, a comprehensive review of the available scientific literature is necessary. The objective of this literature review is to analyze and synthesize relevant studies investigating the use of liraglutide in patients with obesity and type 2 diabetes mellitus, in order to provide a comprehensive view on its effectiveness, indications, complications and management. In conclusion, the use of liraglutide in patients with obesity and type 2 diabetes mellitus has been shown to be an effective therapeutic option to improve glycemic control, promote weight loss and reduce cardiovascular risk. This drug, as a GLP-1 receptor agonist, stimulates insulin secretion, suppresses excessive glucagon release and delays gastric emptying, which contributes to the improvement in glycemic control.
Ortega MA, Fraile-Martínez O, Naya I, García-Honduvilla N, Álvarez-Mon M, Buján J et al. Type 2 diabetes mellitus associated with obesity (diabesity). The central role of gut microbiota and its translational applications. Nutrients. 2020;12(9):2749.
World Health Organization. The state of food security and nutrition in the world 2020: transforming food systems for affordable healthy diets, Vol 2020. Food Agriculture Org. 2020.
Xue T, Li Q, Zhang Q, Lin W, Wen J, Li L, Chen G. Blood glucose levels in elderly subjects with type 2 diabetes during COVID-19 outbreak: a retrospective study in a single center. Medrxiv. 2020.
Karavanaki K, Paschou SA, Tentolouris N, Karachaliou F, Soldatou A. Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management. Endocrine. 2022;78(2):280-95.
Helmstädter J, Frenis K, Filippou K, Grill A, Dib M, Kalinovic S et al. Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arteriosclerosis Thrombosis Vascular Biol. 2020;40(1):145-58.
Unger J, Allison DC, Kaltoft M, Lakkole K, Panda JK, Ramesh C et al. Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA‐PRIME). Diabetes Obesity Metabolism. 2022;24(2):204-11.
Lin CH, Shao L, Zhang YM, Tu YJ, Zhang Y, Tomlinson B et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion Pharmacoth, 2020;21(3):275-85.
Ebell MH. Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Who Take Metformin. Am Family Physician. 2023;107(4):434-4.
Trenson L, Trenson S, Van Nes F, Moyson C, Lannoo M, Deleus E et al. Liraglutide for weight management in the real world: significant weight loss even if the maximal daily dose is not achieved. Obesity Facts, 2022;15(1):83-9.
Webster CM, Mittal N, Dhurandhar EJ, Dhurandhar NV. Potential contributors to variation in weight‐loss response to liraglutide. Obesity Rev. 2023;e13568.
Mirabelli M, Chiefari E, Caroleo P, Arcidiacono B, Corigliano DM, Giuliano S et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes. Int J Environmental Res Pub Health. 2022;17(1):207.
León-Mimila P, Villamil-Ramírez H, Li XS, Shih DM, Hui ST, Ocampo-Medina E et al. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metabolism. 2021;47(2):101183.
Shin J, Kim R, Kim HS. Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice. Cardiovascular Prevention Pharmacotherapy, 2023;5(2):49-53.
Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides. 2019;11126-32.